How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,833 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Symptomatic treatment of the cough in whooping cough. (PubMed)

children (N = 448 participants). Two trials recruited adolescents and adults (N = 130 participants). We considered only three trials to be of high methodological quality (one trial each of diphenhydramine, pertussis immunoglobulin and montelukast). Included studies did not show a statistically significant benefit for any of the interventions. Only six trials, including a total of 196 participants, reported data in sufficient detail for analysis. Diphenhydramine did not change coughing episodes

Full Text available with Trip Pro

2014 Cochrane

182. Honey for acute cough in children. (PubMed)

data on reported outcomes.We included three RCTs, two at high risk of bias and one at low risk of bias, involving 568 children. The studies compared honey with dextromethorphan, diphenhydramine, 'no treatment' and placebo for the effect on symptomatic relief of cough using a seven-point Likert scale. The lower the score, the better the cough symptom being assessed.Moderate quality evidence showed that honey may be better than 'no treatment' in reducing the frequency of cough (mean difference (MD (...) that honey may be slightly better than diphenhydramine in reducing cough frequency (MD -0.57; 95% CI -0.90 to -0.24; one study, 80 participants).Adverse events included mild reactions (nervousness, insomnia and hyperactivity) experienced by seven children (9.3%) from the honey group and two (2.7%) from the dextromethorphan group; the difference was not significant (risk ratio (RR) 2.94; 95% Cl 0.74 to 11.71; two studies, 149 participants). Three children (7.5%) in the diphenhydramine group experienced

Full Text available with Trip Pro

2014 Cochrane

183. A randomized trial of diphenhydramine as prophylaxis against metoclopramide-induced akathisia in nauseated emergency department patients. (PubMed)

A randomized trial of diphenhydramine as prophylaxis against metoclopramide-induced akathisia in nauseated emergency department patients. Akathisia, an adverse effect observed at times after administration of parenteral metoclopramide, is an unpleasant symptom complex characterized by restlessness and agitation. Some try to limit the development of akathisia by coadministering diphenhydramine when using parenteral metoclopramide. The goal of this investigation is to determine whether (...) concomitant administration of diphenhydramine 25 mg decreased the rate of development of akathisia after administration of 10 mg or 20 mg of intravenous metoclopramide.This was a randomized, double-blind, factorial design trial. Patients who presented to our emergency department with a primary or secondary chief complaint of nausea were randomized to one of the following 4 groups: (1) metoclopramide 10 mg+diphenhydramine 25 mg; (2) metoclopramide 10 mg+placebo; (3) metoclopramide 20 mg+diphenhydramine 25

2009 Annals of Emergency Medicine

184. Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V

ibuprofen), diphenhydramine and/or cimetidine, or other H2 receptor antagonists ? after cycle 1, day 14 radiotherapy for alleviation of pain Docetaxel arm: ? granulocyte-stimulating medications ? antiemetics, antiallergics if approved by the investigator Atezolizumab arm: ? = cycle 2 systemic corticosteroids, TNFa inhibitors; epinephrine, antihistamines for the treatment of AEs Non-permitted concomitant treatment: Docetaxel: ? CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin (...) of the interventions – RCT, direct comparison: atezolizumab vs. docetaxel (continued) Concomitant treatment: Concomitant treatment permitted: ? analgesics at a stable dosage at the start of the study ? antipyretics (preferably ibuprofen), diphenhydramine and/or cimetidine, or other H2 receptor antagonists ? megestrol to stimulate appetite ? oral contraceptives, hormone replacement therapy, prophylactic or therapeutic anticoagulants (e.g. low molecular weight heparin or warfarin) at a stable dose ? after cycle 1

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

185. Treatment-Related Nausea and Vomiting (PDQ®): Health Professional Version

Haloperidol 1–4 mg q6h PO, IV, IM Used for treatment [ ][ ] Rarely used for prophylaxis Prolongs QT interval Droperidol 0.625–2.5 mg/dose IV Prolongs QT interval [ , ][ ] Used primarily for treatment Dopamine antagonists: substituted benzamides Metoclopramide Prevention of CINV: 1–2 mg/kg IV x1 dose prechemotherapy; then x2 doses q2h; then x3 doses q3h PO, IM, IV EPS associated with higher doses; patients <30 y [ ] Pretreat with diphenhydramine to prevent EPS Treatment of CINV: 10–40 mg PO q4–6h; up (...) phenothiazines (e.g., chlorpromazine) produce sedation and anticholinergic effects, while piperazines (e.g., prochlorperazine) are associated with less sedation but higher incidence of extrapyramidal symptoms (EPS) (acute dystonias, akathisia, neuroleptic malignant syndrome [uncommon], and, rarely, akinesias and dyskinesias). Marked hypotension may also result if IV doses are administered rapidly at high doses. The concomitant use of H1 blockers, such as diphenhydramine, can often decrease the risk

2018 PDQ - NCI's Comprehensive Cancer Database

187. Gabapentin for Adults with Neuropathic Pain

to 18). RR (95% CI) for one or more adverse events was 1.64 (1.15 to 2.32), favoring placebo. Fibromyalgia (FBM) One systematic review 6 included one RCT (parallel group, N = 150) comparing the effect of gabapentin (2400 mg) with active placebo (diphenhydramine) in patients with FBM. Statistically significant pain relief (assessed as = 30% pain reduction over baseline) was achieved with gabapentin (daily dose 2400 mg) compared to placebo over 12 weeks with RR (95% CI) of 1.6 (1.1 to 2.4 (...) in each RCT SMD (95% CI) a Pain reduction 3 20 4.38 (3.24 to 5.19 38 0.10 (-0.50 to 0.69) b 14 1.27 (0.12 to 2.42 a Results are reported for each individual RCT b In this RCT the placebo was an active placebo (diphenhydramine) Adverse events with gabapentin compared with placebo for SCI (results from I RCT with 20 patients) Outcome OR (95% CI) Dizziness 3.35 (0.32 to 35.36 Edema 8.20 (0.40 to 169.90) Headache 1.00 (0.06 to17.18) Sedation 8.20 (0.40 to 169.90 Weakness 3.00 (0.51 to 17.74) Gabapentin

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

190. Ferumoxytol versus Other Intravenous Iron Therapies for Anemia

with ferumoxytol. 3 All studies 1-3,9 reported between one and two anaphylactic responses associated with iron infusion, (although one did not term this anaphylaxis; however, the patient was treated with diphenhydramine and steroids, with symptoms resolving within minutes 10 ) which seems to correlate with most other studies that examine IV infusions with iron or a derivative thereof. 4 The anaphylactic reaction frequency ranged between 0.02% to 1.3% of patients treated with ferumoxytol. 1-3,9 No patients

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

191. A Comparison of Headache Treatment in the Emergency Department: Prochlorperazine Versus Ketamine

with a convenience sample of patients presenting to the ED with benign headaches. Patients were randomized to receive either prochlorperazine and diphenhydramine or ketamine and ondansetron. Patients' headache severity was measured on a 100-mm visual analog scale (VAS) at 0, 15, 30, 45, and 60 minutes. Nausea, vomiting, anxiety, and the need for rescue medications were also tracked. Patients were contacted at 24 to 48 hours posttreatment to rate their satisfaction and to determine whether they were still

2017 EvidenceUpdates

192. Tisagenlecleucel (Kymriah) - treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL)

(500mg/m 2 intravenously for two days starting with the first dose of fludarabine). It is recommended that tisagenlecleucel is infused two to 14 days after completion of the lymphodepleting chemotherapy. The availability of tisagenlecleucel must be confirmed prior to starting the lymphodepleting regimen. To minimise potential acute infusion reactions, it is recommended that patients be pre- medicated with paracetamol and diphenhydramine (or another H1 antihistamine) approximately 30 to 60 minutes (...) ). A single 5 intravenous infusion of tisagenlecleucel was given at the maximum dose within the range that could be manufactured: target dose range of 2.0 to 5.0×10 6 tisagenlecleucel cells per kg body weight for patients =50 kg and of 1.0 to 2.5×10 8 tisagenlecleucel cells per kg for patients >50 kg. Patients were given premedication with paracetamol and diphenhydramine or an H1 antihistamine every six hours as needed. 2 Of the 92 patients enrolled, 75 received tisagenlecleucel. The reasons

2019 Scottish Medicines Consortium

193. Axicabtagene ciloleucel (Yescarta) - Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL)

intravenous and fludarabine 30mg/m 2 intravenous should be administered on the fifth, fourth, and third day before infusion of axicabtagene ciloleucel. Pre-medication: Paracetamol 500mg to 1,000mg given orally and diphenhydramine 12.5mg intravenous or oral (or equivalent) approximately one hour before axicabtagene ciloleucel infusion is recommended. Axicabtagene ciloleucel must be administered in a qualified clinical setting. Axicabtagene ciloleucel should be initiated under the direction

2019 Scottish Medicines Consortium

194. Intravenous Fluid for the Treatment of Emergency Department Patients With Migraine Headache: A Randomized Controlled Trial. (PubMed)

(fluid group) or saline solution at 10 mL/hour for 1 hour (control group). All patients received intravenous prochlorperazine and diphenhydramine at the start of fluid administration. Participants and outcome assessors were blinded; nurses administering the intervention were not. Outcomes were assessed at 60 and 120 minutes, and 48 hours. The primary outcome was the difference in the verbal pain rating (on a scale of 0 to 10) between 0 and 60 minutes. Key secondary outcomes included additional

2019 Annals of Emergency Medicine

195. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. (PubMed)

received fremanezumab, with a total exposure of 390.4 patient years and maximum exposure of 181 days. AEs were mostly mild to moderate in severity and were reported among 48-69% of patients in all treatment groups, and most were injection site reactions (pain, induration, and erythema). Two deaths occurred (chronic obstructive pulmonary disease and intentional overdose of diphenhydramine), both of which were deemed unrelated to study drug by the investigators and sponsor. Cardiovascular adverse events

2019 Headache

196. What are the best treatments for benign migratory glossitis? (PubMed)

reviewer was available to resolve discrepancies. A narrative summary of the findings was presented.Results Eleven studies involving a total of 150 patients contributed to the review. A majority (eight) were considered to be of very low quality, one of low quality, one of moderate quality and one of high quality. A range of treatments were employed, the most common being triamcinolone acetonide 0.1% (n = 2), topical tacrolimus 0.1% (n = 2), topical diphenhydramine (n = 2), and nutritional supplements (n

2019 Evidence Based Dentistry

197. The THINK (Treatment of Headache with Intranasal Ketamine) Trial: A Randomized Controlled Trial Comparing Intranasal Ketamine with Intravenous Metoclopramide. (PubMed)

The THINK (Treatment of Headache with Intranasal Ketamine) Trial: A Randomized Controlled Trial Comparing Intranasal Ketamine with Intravenous Metoclopramide. Headache is a common chief complaint in the emergency department (ED) setting.To compare analgesia with metoclopramide and diphenhydramine vs. intranasal ketamine among ED patients with primary headache.We enrolled a convenience sample of adults with a primary headache in a randomized, single-blind, placebo-controlled trial. We randomized (...) patients to either a control arm (intravenous metoclopramide and diphenhydramine) or intranasal ketamine. The primary outcome was change in pain 0-100 mm visual analog scale (VAS) score measured at study start and 30 min post completion of initial medication administration. Secondary outcomes included side effects, hospital admission, and return to care within 48-72 h.All 53 enrolled subjects completed the study, 26 of whom were allocated to the control arm and 27 to intranasal ketamine. The mean

2019 Journal of Emergency Medicine

198. Intravenous lidocaine in the management of chronic peripheral neuropathic pain: a randomized-controlled trial. (PubMed)

). Our objective was to determine if IV lidocaine provides significant pain relief and overall improvement in quality of life in the longer term (for up to four weeks).This single site randomized double-blind, crossover trial compared IV lidocaine infusion (5 mg·kg-1) with active placebo infusion containing diphenhydramine (50 mg) in patients with chronic neuropathic pain of peripheral nerve origin of at least six months duration. The primary outcome was average pain intensity reduction from IV

2019 Canadian Journal Of Anaesthesia

199. Asthma associated with denatonium benzoate in a healthcare worker in Taiwan: A case report. (PubMed)

with omalizumab (Xolair), corticosteroid, β2 agonist, montelukast, and Symbicort turbuhaler.The patient showed quick responses after treatment with diphenhydramine (intramuscularly), fenoterol HBr (inhalation), and prednisolone (oral). Approximately 2 weeks later, she suffered from difficulty breathing and asthmatic symptoms again when she was exposed to polished wax and disinfectant. She was treated with omalizumab (Xolair), corticosteroid, β2 agonist, montelukast, and Symbicort turbuhaler. The patient

2019 Medicine

200. A revisit to the effects of zinc salt on skin burn wound healing to reflect the risks in current pharmaceutical care. (PubMed)

responsible for the late adverse effects such as pruritis and inflammation reported with calamine/diphenhydramine lotion, medicated shampoo, Olay Complete defense moisturizing lotion and Zineryt® topical solution. The skin irritation was likely a resultant oxidative stress action of soluble zinc, where a small fraction could be adequate to negate the skin homeostasis. Key messages Zinc is essentially a cofactor for skin collagen formation. Soluble zinc content as low as 10.5 μg/cm2 of skin irritates skin

2019 Journal of Dermatological Treatment

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>